Concepedia

Evan A. Mulligan

EA

15

Publications

1.2K

Citations

15

H-Index

1998

Active since

Affiliations

Newcastle University(Current)

Pfizer (United States)

Agroscope

Laboratoire de Biologie et Modélisation de la Cellule

Freeman Hospital

Evan A. Mulligan is an author at Newcastle University specializing in medicine, cell biology, and oncology.

Top concepts

Publications per year

1998–2015

15

Publications

15

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

Yvette Drew, Evan A. Mulligan, Wan-Tse Vong et al. · JNCI Journal of the National Cancer Institute · 2010 · 257 citations · Full text

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Ruth Plummer, Paul Lorigan, Neil Steven et al. · Cancer Chemotherapy and Pharmacology · 2013 · 175 citations

, , +8

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

Natalia Issaeva, Huw D. Thomas, Tatjana Djurenovic et al. · Cancer Research · 2010 · 104 citations · Full text

, , +14

Influence of Bt-transgenic pollen, Bt-toxin and protease inhibitor (SBTI) ingestion on developmentof the hypopharyngeal glands in honeybees

D. Babendreier, Nicole M. Kalberer, Jörg Romeis et al. · Apidologie · 2005 · 93 citations · Full text

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan et al. · Molecular Cancer Therapeutics · 2009 · 91 citations · Full text

Rows per page

1–5 of 15